Evidence map›Paper›PMID 41378909›Full record

ArticlemBio2026

EBNA1 SUMOylation by PIAS1 suppresses EBV lytic replication and enhances episome maintenance.

Febri Gunawan Sugiokto, Kun Zhang, Yunash Maharjan, Renfeng Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in mBio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

4 authors.

Febri Gunawan SugioktoProgram in Microbiology and Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0009-0004-2097-2744
Kun ZhangDepartment of Oral and Craniofacial Molecular Biology, School of Dentistry, Virginia Commonwealth University, Richmond, Virginia, USA.ORCID 0000-0001-5696-2426
Yunash MaharjanProgram in Microbiology and Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0003-0453-9778
Renfeng LiProgram in Microbiology and Immunology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.ORCID 0000-0002-9226-4470

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 1988 to 2026
$158.0M
The Role of PIAS1 in EBV BiologyR01AI141410 · NIAID · VIRGINIA COMMONWEALTH UNIVERSITY · PI LI, RENFENG · 2019 to 2023
$1.9M
ASB13 Control of EBV Life Cycle in B Cell and Epithelial Cell CancersR01AI187186 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Renfeng Li · 2025 to 2026
$1.4M
American Cancer Society 134703-RSG-20-054-01-MPCNCI NIH HHS P30 CA047904NIAID NIH HHS R01 AI141410NIAID NIH HHS R01 AI187186
6 · The paper itself

Abstract

Epstein-Barr virus nuclear antigen 1 (EBNA1) is essential for the replication and stable maintenance of the viral episome in infected cells. Here, we identify the SUMO E3 ligase PIAS1 as a key regulator of EBNA1 through site-specific SUMOylation. Our chromatin immunoprecipitation sequencing analysis revealed that PIAS1 is enriched at the viral origin of plasmid replication (

Indexed as

Epstein-Barr Virus Nuclear AntigensHerpesvirus 4, HumanPlasmidsProtein Inhibitors of Activated STATSmall Ubiquitin-Related Modifier ProteinsSumoylationVirus ReplicationCell LineHEK293 CellsHumansEBV-encoded nuclear antigen 1Epstein-Barr Virus Nuclear AntigensPIAS1 protein, humanProtein Inhibitors of Activated STATSmall Ubiquitin-Related Modifier ProteinsEBNA1episomeEpstein-Barr viruslatencyorigin of plasmid replication (oriP)PIAS1SUMOylation

Identifiers

PMID41378909
PMCPMC12802318

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.